Mitochondrial DNA variations and evidence of haplogroups in Indian Friedreich's ataxia (FRDA) patients. I. Mudila, F. Mohammed, A. Srivastava; Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Pages e708-e709. http://dx.doi.org/10.1016/j.jns.2013.07.2446
Variations at positions 16 519, 4883 and 5178 suggest that these variations may act as modifier for the disease.
Saturday, September 21, 2013
Voxel-based morphometry in Friedreich's ataxia: A prospective study
Voxel-based morphometry in Friedreich's ataxia: A prospective study. C. Bonilha da Silva, C.L. Yasuda, A. D'Abreu, I. Lopes-Cendes, F. Cendes, M.C. França Jr.; Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Pages e659-e660. http://dx.doi.org/10.1016/j.jns.2013.07.2285
VBM analyses showed that FRDA patients have progressive GM and WM loss in two years
VBM analyses showed that FRDA patients have progressive GM and WM loss in two years
Electrophysiological study of spinocerebellar ataxia and Friedreich ataxia's patients
Electrophysiological study of spinocerebellar ataxia and Friedreich ataxia's patients. B. Myftiu, E. Kocasoy Orhan, B. Baslo, Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Page e477. http://dx.doi.org/10.1016/j.jns.2013.07.1697
Interferon gamma as a potential therapy for Friedreich ataxia
Interferon gamma as a potential therapy for Friedreich ataxia. B. Tomassini, G. Arcuri, S. Fortuni, C. Sandi, V. Ezzatizadeh, C. Casali, I. Condo, F. Malisan, S. Al-Mahdawi, M. Pook, R. Testi; Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Page e474. http://dx.doi.org/10.1016/j.jns.2013.07.1686
Treatment with interferon gamma, a drug currently approved for pediatric indications, shows potential as a therapy for FRDA. A phase II clinical trial, aimed at assessing tolerability of interferon gamma and the ability of interferon gamma to elevate frataxin levels in FRDA patients, is currently underway
Treatment with interferon gamma, a drug currently approved for pediatric indications, shows potential as a therapy for FRDA. A phase II clinical trial, aimed at assessing tolerability of interferon gamma and the ability of interferon gamma to elevate frataxin levels in FRDA patients, is currently underway
Autosomal recessive cerebellar ataxia: A clinical and genetic study
Autosomal recessive cerebellar ataxia: A clinical and genetic study. L. Ali-Pacha, W. Hamza, S. Nouioua, C. Lagier-Tourenne, S. Assami, T. Benhassine, M. Koenig, M. Tazir. Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Page e468. http://dx.doi.org/10.1016/j.jns.2013.07.1665
Friedreich's ataxia was the most frequent entity, as found in the majority of studies, followed by AOA2 and AVED.
Friedreich's ataxia was the most frequent entity, as found in the majority of studies, followed by AOA2 and AVED.
Substantia nigra hypoechogenicity is not related to Friedreich ataxia
Substantia nigra hypoechogenicity is not related to Friedreich ataxia. M. Sierra, J. Infante, J. Berciano; Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Pages e146-e147. http://dx.doi.org/10.1016/j.jns.2013.07.488
Our data do not support the notion that SN hypoechogenicity is related to FRDA itself, although it might be associated with RLS.
Our data do not support the notion that SN hypoechogenicity is related to FRDA itself, although it might be associated with RLS.
Pseudo-dominant' inheritance in Friedreich's ataxia: Clinical and genetic study of a Brazilian family
Pseudo-dominant' inheritance in Friedreich's ataxia: Clinical and genetic study of a Brazilian family. F.M. Branco Germiniani, A. Moro, R. Munhoz, W.O. Arruda, S. Raskin, A. Martinez, H.A.G. Teive; Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Page e113. http://dx.doi.org/10.1016/j.jns.2013.07.381
KEYWORDS: progressive ataxia, dysarthria, dysphagia, generalized ataxia, dysmetria, loss of deep tendon reflexes, MRI, cardiomyopathy, expanded alleles, pseudodominant inheritance, intra-familial clinical polymorphism.
KEYWORDS: progressive ataxia, dysarthria, dysphagia, generalized ataxia, dysmetria, loss of deep tendon reflexes, MRI, cardiomyopathy, expanded alleles, pseudodominant inheritance, intra-familial clinical polymorphism.
Chlorophyllin: A possible new therapeutic agent for increasing frataxin levels in Friedreich'/INS;s ataxia patients
Chlorophyllin: A possible new therapeutic agent for increasing frataxin levels in Friedreich'/INS;s ataxia patients. B. Sturm, B. Gmeiner, M. Hermann, B. Scheiber-Mojdehkar; Journal of the Neurological Sciences, Volume 333, Supplement 1, 15 October 2013, Page e71
Keywords: frataxin expression, chlorophyllins, unknown mechanism, green plant pigment chlorophyll, dietary, medicinal, antimutagenic, antigenotoxic, anticarcinogenic.
Keywords: frataxin expression, chlorophyllins, unknown mechanism, green plant pigment chlorophyll, dietary, medicinal, antimutagenic, antigenotoxic, anticarcinogenic.
Subscribe to:
Posts (Atom)